A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin

• Status: Completed
• Trial end date: 1998-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

Lifibrol is a new lipid-lowering drug which lowers cholesterol to an extent in the order of magnitude of the statins. The mechanism of action of this compound is different from the one of statins but remains unknown. The current study will investigate the mechanism of action using stable-isotope turnover methods. The study will be done in healthy male volunteers.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Bonn
• Treatments: Pravastatin

Criteria

Inclusion Criteria:

• male volunteers

• 18 to 35 years old

• good clinical condition

• normal eating habits

• mental abilities to be able to understand the study procedures

• written informed consent

Exclusion Criteria:

• relevant pathological findings in the baseline examination

• known allergic predisposition

• concomitant drugs

• alcohol or nicotine abuse

• participation in other clinical trials in the last 30 days